^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DI Leu16 IL-2
i
Other names: DI Leu16 IL-2, de-immunized form of the Leu16 anti-CD20 antibody fused to IL-2 , DI-Leu16-IL2, DI-Leu16-IL2 immunocytokine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Alopexx, EMD Serono, Provenance, Shenogen Pharma
Drug class:
CD20 inhibitor, Immunostimulant, IL-2 stimulant
Related drugs:
4years
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL (clinicaltrials.gov)
P1/2, N=5, Terminated, Alopexx Oncology, LLC | Completed --> Terminated; Clinical benefit was noted before the scheduled completion of the trial and the extension study was terminated early.
Clinical • Trial termination
|
IL2 (Interleukin 2)
|
DI Leu16 IL-2
4years
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL (clinicaltrials.gov)
P1/2, N=24, Terminated, Alopexx Oncology, LLC | Completed --> Terminated; Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.
Clinical • Trial termination
|
CD20 (Membrane Spanning 4-Domains A1) • IL2 (Interleukin 2)
|
CD20 expression
|
DI Leu16 IL-2
Share via
